研究论文

碳酸铯促进N-(8-氨基喹啉)-3-丁烯酰胺与三甲基硅氰的氢氰化反应

  • 朱晓龙 ,
  • 崔靖 ,
  • 曾润生 , *
展开
  • 苏州大学材料与化学化工学部 江苏苏州 215000

收稿日期: 2024-11-23

  修回日期: 2025-01-19

  网络出版日期: 2025-01-24

基金资助

江苏省前瞻性研究(2020114)

Cesium Carbonate-Promoted Hydrocyanide Reaction of N-(Quinolin-8-yl)but-3-enamides and Trimethylsilyl Cyanide

  • Xiaolong Zhu ,
  • Jing Cui ,
  • Runsheng Zeng , *
Expand
  • College of Chemistry, Chemical Engineering and Materials Science of Scoohow University, Suzhou, Jiangsu 215000

Received date: 2024-11-23

  Revised date: 2025-01-19

  Online published: 2025-01-24

Supported by

Prospective Study Program of Jiangsu Province(2020114)

摘要

报道了碳酸铯促进的N-(8-氨基喹啉)-3-丁烯酰胺的氢氰化反应, 以8-氨基喹啉作为导向基团保护的3-丁烯酸为原料, 与三甲基硅氰在90 ℃下进行反应, 得到了一系列3-氰基丁酰胺衍生物. 机理研究表明, 该反应为双键的亲核加成反应而非自由基反应.

本文引用格式

朱晓龙 , 崔靖 , 曾润生 . 碳酸铯促进N-(8-氨基喹啉)-3-丁烯酰胺与三甲基硅氰的氢氰化反应[J]. 有机化学, 2025 , 45(7) : 2529 -2536 . DOI: 10.6023/cjoc202409043

Abstract

A novel Cs2CO3-promoted hydrocyanide reaction of the directing group-protected N-(quinolin-8-yl)but-3-enamides with trimethylsilyl cyanide to afford 3-cyanobutylamides is described. Mechanistic studies have shown that this reaction is a nucleophilic addition reaction of double bonds rather than a free radical reaction.

氰基不仅仅是许多药物和生物活性化合物的关键组成部分, 还是一个重要的、用途广泛的基团. 氰基可以通过反应很容易地转化为各种其他基团, 例如通过还原可以转换为伯胺, 通过水解可以转换为酰胺、羧酸 等[1-5]. 因此, 氰基是制备药物中间体的重要基团[6-13]. 在分子中引入氰基的主要反应包括: 卤素、重氮盐以及酯基被氰基取代的取代反应, 含有C=X (X为C、O、N等)或C≡C基团的化合物与HCN的加成反应, 以及化合物通过脱除分子内的一分子水进而构建氰基的消除反应[14]. 但是上述方案普遍使用含有剧毒的金属氰化物或者含有剧毒的HCN作为氰基源, 在反应中往往具有巨大的安全隐患, 与绿色化学的原则相违背. 所以开发安全的、低毒的引入氰基的方法是十分有必要的.
烯烃的双键和炔烃的叁键均可以用于构建复杂的分子结构, 而烯烃的双键官能化反应已成为有机合成方向的热门研究领域[15]. 在已经开发的方法中, 原子转移自由基加成法(ATRA)是一种简便的实现烯烃双官能化的方法, 可以一步形成相邻的碳-碳或碳-杂原子键, 但由于转化率、选择性和产率等方面问题, 仍然面临许多挑战, 而关于烯烃的氢氰化反应研究文献报道较少. 2017年, 邹建平课题组[16]介绍了一种烯烃的双官能团化反应, 以Mn(OAc)3为介导CuCN催化的磷酸酰基自由基加成的氰化反应, 得到了邻氰膦酰化产物. 2019年, 林松课题组[17]建立了电催化反应作为一种广泛适用的烯烃双官能化策略, 既由电化学生成自由基中间体, 通过控制自由基对烯烃进行加成反应. 2020年, 鲍红丽课题组[18]报道了一种铜催化的烯烃不对称氰基(氟)烷基化反应. 在该反应中, 过氧化物LPO在自由基不对称反应中起着重要的促进作用, 为氟烷基碘化物作为烷基源的烯烃对映选择性三组分氟烷基化反应提供了新的思路. 2022年, 黄国保课题组[19]发表了最近五年来电化学介导不饱和烃的双官能团化反应中的最新研究进展. 2024年, 万洁平课题组[20]发表了自2018年至2023年间烯烃和炔烃电化学双官能化合成有机糖原的最新进展.
在烯烃的官能团化反应中, 氰基化反应普遍使用的原料是TMSCN. 一般来说, TMSCN作为一种亲核试剂, 它常常释放出氰基负离子对双键进行亲核加成反应[21]. 本文报道了以TMSCN作为氰基源, 碳酸铯促进的N-(8-氨基喹啉)-3-丁烯酰胺的氢氰化反应(Scheme 1).
图式1 N-(8-氨基喹啉)-3-丁烯酰胺的氢氰化反应

Scheme 1 Hydrocyanation of N-(quinoline-8-yl)but-3-enamides

1 结果与讨论

首先, 使用以8-氨基喹啉为导向基团的丁烯酰胺衍生物1a作为模板底物和TMSCN反应, 乙腈作为溶剂, 80 ℃下搅拌12 h, 以71%的收率获得目标产物(Table 1, Entry 3). 随后, 使用不同的碱、不同的温度在不同的溶剂中进行反应(Table 1, Entries 1~13), 结果表明, 碳酸铯可以促进反应有效进行, 而选择使用其他路易斯碱, 如碳酸钾、碳酸钠、碳酸氢钠以及磷酸钾等得到较少或者不能得到目标产物3a; N,N-二甲基甲酰胺(DMF)是最好的反应溶剂.
表1 反应条件的优化a

Table 1 Optimization of reaction conditions

Entry T/℃ Base Solvent Yieldb/%
1 60 CsCO3 CH3CN 11
2 70 CsCO3 CH3CN 39
3 80 CsCO3 CH3CN 71
4 90 CsCO3 CH3CN 76
5 100 CsCO3 CH3CN 69
6 110 CsCO3 CH3CN 54
7 90 K2CO3 CH3CN Trace
8 90 K2PO4 CH3CN Trace
9 90 Na2CO3 CH3CN 45
10 90 CsCO3 DMSO 77
11 90 CsCO3 t-Butanol 23
12 90 CsCO3 DMF 89
13 90 CsCO3 Toluene 43

a General conditions: 1a (0.2 mmol), 2a (0.4 mmol), base (0.6 mol, 3 equiv.), H2O (0.12 mmol) and solvent (3.0 mL) at 90 ℃. b Isolated yield.

在最佳反应条件下对底物的普适性进行了实验(Table 2). 在标准条件下对于大多数α-取代的丁烯酰胺类衍生物都可以达到良好的收率, 如取代基为乙基、甲基等基团时收率良好. 当α-取代基为烯丙基时, 虽然底物中存在两个C=C双键, 但是没有观察到两个双键都发生的氢氰化反应. 此外, 研究结果还表明α-取代基为对位取代的苄基时, 反应的收率会有所降低.
表2 氢氰化反应底物拓展研究a,b

Table 2 Scope studies of the substrate of hydrocyanide reaction

a General conditions: 1 (0.2 mmol), 2 (0.4 mmol), H2O (0.12 mmol) and DMF (2.0 mL) at 90 ℃. b Yields of isolated products are given.

为了进一步验证8-氨基喹啉作为导向基的作用, 做了烯烃的选择性实验(Scheme 2), 均没有观察到相应的加成产物3的生成. 实验结果表明在该反应中8-氨基喹啉基作为导向基是必须的, 猜想可能是8-氨基喹啉的存在促进了水与双键的加成, 随后在碱的作用下脱水形成不饱和酮.
图式2 烯烃的选择性实验

Scheme 2 Selective experiment of olefins

同时对该反应进行了放大实验, 保持原料以及碱的物质的量比不变, 水的量变为3 equiv., 底物1a的用量放大至4 mmol, 得到收率为81%的放大产物(Scheme 3).
图式3 克级实验

Scheme 3 Gram level experiment

为了探索反应的机理, 进行了控制实验(Scheme 4), 在相同的反应条件下加入自由基捕捉剂2,2,6,6-四甲基哌啶氧化物(TEMPO), 反应体系中没有发现自由基捕捉的产物, 说明该反应未经历自由基的反应过程(Scheme 4a).
图式4 机理验证

Scheme 4 Mechanism verification

另外, 还做了碳酸铯和水的控制实验(Scheme 4b), 结果表明反应中加入碳酸铯和水是必须的, 加入适量的水可以促进反应进行, 提高收率. 氘代实验(Scheme 4b)结果表明, 氘加到了双键末端, 同时观察到了烯醇异构化的氘代产物, 产物的总氘代率通过比较核磁共振氢谱(1H NMR)中产物的氘取代氢位置的积分和非氘取代对照物的氢位置的积分来确定[22], 经计算可得, 3a的氘代率99%. 该结果也说明水作为原料参与了反应.
基于上述实验的结果, 提出了可能的反应机理(Scheme 5). 原料1a在碱的作用下生成中间体A, A通过双键异构化产生B; B夺取水分子中质子生成C, 同时TMSCN和碱反应生成了CN, C与CN发生双键上的亲核加成反应生成D, D夺去水中的质子得到产物3a, 并再生氢氧根离子.
图式5 可能的反应机理

Scheme 5 Proposed reaction mechanism

2 结论

本文首次报道了碳酸铯促进的N-(8-氨基喹啉)-3-丁烯酰胺的氢氰化反应, 以8-氨基喹啉作为导向基团保护的3-丁烯酸为原料, 以TMSCN为氰基源, 去离子水为氢源, 通过双键的亲核加成反应, 成功构建了N-(8-氨基喹啉)-3-丁烯酰胺的氢氰化反应, 得到了一系列3-氰基丁酰胺衍生物. 研究结果还表明, 反应无需添加铜催化剂、氧化剂和配体.

3 实验部分

3.1 仪器与试剂

Bruker Avance III核磁共振仪, 1H NMR和13C NMR以TMS为内标; TOF-MS (EI or ESI)高分辨质谱仪; Perkin Elmer Clarus 680气相色谱仪; Bruker Scion SQ 436气质色谱仪; ZORBAX Eclipse XDB-C18液相色谱仪. 所有试剂均为分析纯.

3.2 实验方法

3.2.1 取代的N-(喹啉-8-基)丁-3-烯酰胺(1)的合成

向100 mL的单口烧瓶中加入二异丙基氨基锂(LDA) (11.8 mL, 23.5 mmol), 降温至0 ℃, 将3-丁烯酸 (1 mL, 11.77 mmol)和10 mL的四氢呋喃溶液缓慢加入, 反应45 min, 加入1.1 equiv.的卤代烷烃试剂, 继续反应30 min, 室温下再搅拌1 h. 反应结束后用10%的稀盐酸调整pH=2.5. 用二氯甲烷(15 mL×3)萃取, 合并有机相后, 用饱和食盐水(25 mL×2)洗涤, 最后用无水硫酸钠干燥, 减压浓缩除去乙酸乙酯得到粗产物.
向250 mL的单口烧瓶中加入二氯甲烷(30 mL), 丁烯酸或上述方法制备的取代的丁烯酸(12 mL), 8-氨基喹啉(1.44 g, 10 mL)和N,N,N',N'-四甲基-O-(7-氮杂苯并三唑-1-基)六氟磷酸脲(HATU) (4.94 g, 13 mmol), 室温下搅拌3~5 min,然后加入吡啶(2.6 mL, 20 mmol), 继续反应16 h. 反应结束后向体系中加入200 mL的二氯甲烷, 分别用100 mL的饱和碳酸氢钠溶液和100 mL的饱和食盐水各洗涤一次, 有机相用无水硫酸钠干燥,减压浓缩, 通过柱层析[V(石油醚)∶V(乙酸乙酯)=20∶1]纯化得到原料1.
N-(喹啉-8-基)丁-3-烯酰胺(1a): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.86 (s, 1H), 8.77 (dd, J=7.6, 1.4 Hz, 1H), 8.63 (dd, J=4.2, 1.7 Hz, 1H), 7.89 (dd, J=8.3, 1.7 Hz, 1H), 7.38~7.26 (m, 2H), 7.21 (dd, J=8.3, 4.2 Hz, 1H), 6.13 (dd, J=16.9, 10.3 Hz, 1H), 5.40~5.23 (m, 2H), 3.29 (dt, J=7.1, 1.4 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ: 168.75, 147.89, 138.01, 135.84, 134.17, 131.02, 127.52, 126.85, 121.31, 121.28, 119.52, 116.03, 42.80; HRMS (ESI-TOF) calcd for C13H13N2O [M+H] 213.1028, found 213.1029.
2-(环丙基甲基)-N-(喹啉-8-基)丁-3-烯酰胺(1b): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.87 (s, 1H), 8.69~8.63 (m, 2H), 8.01 (dd, J=8.3, 1.7 Hz, 1H), 7.42~7.34 (m, 2H), 7.31 (dd, J=8.3, 4.2 Hz, 1H), 5.96 (ddd, J=17.1, 10.2, 8.6 Hz, 1H), 5.27~5.13 (m, 2H), 3.19 (d, J=8.0 Hz, 1H), 1.75~1.65 (m, 1H), 1.58~1.52 (m, 1H), 0.68 (dd, J=7.8, 6.6 Hz, 1H), 0.40~0.23 (m, 2H), 0.01 (d, J=4.5 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ: 172.15, 148.23, 138.57, 137.09, 136.31, 134.55, 127.95, 127.42, 121.56, 121.46, 117.77, 116.41, 53.95, 37.29, 9.04, 4.72, 4.60; HRMS (ESI-TOF) calcd for C17H19N2O [M+H] 267.1501, found 267.1499.
N-(喹啉-8-基)-2-乙烯基戊-4-烯酰胺(1c): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 10.00 (s, 1H), 8.88~8.73 (m, 2H), 8.13 (dd, J=8.3, 1.7 Hz, 1H), 7.57~7.37 (m, 3H), 6.04 (ddd, J=17.2, 10.2, 8.5 Hz, 1H), 5.86 (ddt, J=17.1, 10.2, 6.9 Hz, 1H), 5.51~5.26 (m, 2H), 5.26~5.01 (m, 2H), 3.29 (dt, J=7.5, 0.9 Hz, 1H), 2.83~2.70 (m, 1H), 2.50 (dd, J=14.3, 7.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ: 171.30, 148.25, 138.57, 136.38, 136.30, 135.39, 134.44, 128.47, 128.37, 127.94, 127.38, 121.58, 118.49, 117.08, 116.45, 53.03, 36.14; HRMS (ESI- TOF) calcd for C16H17N2O [M+H] 253.1301, found 253.1302.
2-甲基-N-(喹啉-8-基)丁-3-烯酰胺(1d): 淡黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.96 (s, 1H), 8.72 (ddd, J=9.1, 5.7, 1.7 Hz, 2H), 8.08 (dd, J=8.2, 1.7 Hz, 1H), 7.56~7.33 (m, 3H), 6.04 (ddd, J=17.2, 10.2, 7.8 Hz, 1H), 5.35~5.21 (m, 2H), 3.39~3.24 (m, 1H), 1.38 (d, J=7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ: 148.25, 138.62, 138.00, 136.31, 127.95, 127.41, 121.56, 121.49, 117.29, 116.38, 47.02, 16.96; HRMS (ESI-TOF) calcd for C14H15N2O [M+H] 227.1103, found 227.1102.
2-乙基-N-(喹啉-8-基)丁-3-烯酰胺(1e): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.97 (s, 1H), 8.86~8.72 (m, 2H), 8.13 (dd, J=8.3, 1.7 Hz, 1H), 7.63~7.39 (m, 3H), 6.02 (ddd, J=17.2, 10.1, 8.6 Hz, 1H), 5.42~5.20 (m, 2H), 3.18~2.98 (m, 1H), 2.04 (ddd, J=13.7, 7.4, 6.5 Hz, 1H), 1.84~1.64 (m, 1H), 1.01 (t, J=7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ: 172.14, 148.22, 138.55, 136.83, 136.31, 134.53, 127.94, 127.39, 121.56, 121.48, 118.16, 116.41, 55.12, 25.11, 11.82; HRMS (ESI-TOF) calcd for C15H17N2O [M+H] 241.1303, found 241.1305.
N-(喹啉-8-基)-2-乙烯基庚-6-烯酰胺(1f): 淡黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.98 (s, 1H), 8.92~8.70 (m, 2H), 8.13 (dd, J=8.3, 1.7 Hz, 1H), 7.63~7.33 (m, 3H), 6.10~5.98 (m, 1H), 5.93~5.74 (m, 1H), 5.49~5.24 (m, 2H), 5.17~4.92 (m, 2H), 3.35~3.16 (m, 1H), 2.16~1.96 (m, 3H), 1.71 (dddd, J=13.3, 10.6, 7.8, 5.4 Hz, 1H), 1.60~1.43 (m, 2H); 13C NMR (101 MHz, CDCl3) δ: 172.04, 148.23, 138.54, 138.47, 136.96, 136.31, 134.50, 127.94, 127.39, 121.58, 121.51, 118.12, 116.42, 114.78, 53.37, 33.62, 31.39, 26.56; HRMS (ESI-TOF) calcd for C18H21N2O [M+H] 281.1603, found 281.1600.
2-环己基-N-(喹啉-8-基)丁-3-烯酰胺(1g): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.90 (s, 1H), 8.91~8.74 (m, 2H), 8.09 (dd, J=8.3, 1.7 Hz, 1H), 7.60~7.37 (m, 3H), 6.09~5.87 (m, 1H), 5.45~5.13 (m, 2H), 2.88 (t, J=8.9 Hz, 1H), 1.90~1.59 (m, 5H), 1.36~0.90 (m, 5H); 13C NMR (101 MHz, CDCl3) δ: 172.06, 148.19, 138.47, 136.29, 135.96, 134.48, 127.92, 127.36, 121.56, 121.48, 118.41, 116.42, 60.73, 39.74, 31.47, 30.25, 26.37, 26.22; HRMS (ESI-TOF) calcd for C19H23N2O [M+H] 295.1704, found 295.1701.
N-(喹啉-8-基)-2-乙烯基壬酰胺(1h): 白色固体, m.p. 107~108 ℃; 1H NMR (400 MHz, CDCl3) δ: 9.98 (s, 1H), 8.91~8.75 (m, 2H), 8.10 (dd, J=8.3, 1.7 Hz, 1H), 7.63~7.34 (m, 3H), 6.02 (ddd, J=17.1, 10.2, 8.6 Hz, 1H), 5.51~5.20 (m, 2H), 3.17 (q, J=7.7 Hz, 1H), 1.98 (ddd, J=13.1, 8.5, 4.8 Hz, 1H), 1.76~1.60 (m, 1H), 1.49~1.17 (m, 10H), 0.93~0.79 (m, 3H); 13C NMR (101 MHz, CDCl3) δ: 172.20, 148.19, 138.53, 137.15, 136.27, 134.54, 127.91, 127.36, 121.54, 121.45, 117.89, 116.39, 53.54, 31.98, 31.83, 29.49, 29.17, 27.27, 22.65, 14.10; HRMS (ESI-TOF) calcd for C20H27N2O [M+H] 311.1994, found 311.2000.
2-(4-甲基苄基)-N-(喹啉-8-基)丁-3-烯酰胺(1i): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.91 (s, 1H), 8.87~8.49 (m, 2H), 7.89 (dd, J=8.3, 1.7 Hz, 1H), 7.40 (t, J=8.0 Hz, 1H), 7.30 (dd, J=8.3, 1.4 Hz, 1H), 7.20 (dd, J=8.3, 4.2 Hz, 1H), 7.12 (d, J=8.0 Hz, 2H), 7.00 (d, J=7.9 Hz, 2H), 6.04 (ddd, J=17.1, 10.2, 8.5 Hz, 1H), 5.30~5.15 (m, 2H), 3.57~3.26 (m, 2H), 2.93 (dd, J=13.7, 7.4 Hz, 1H), 2.19 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 171.29, 148.17, 138.45, 136.59, 136.18, 136.12, 135.71, 134.52, 129.19, 129.16, 127.88, 127.28, 121.62, 121.55, 118.60, 116.45, 55.26, 37.87, 21.12; HRMS (ESI-TOF) calcd for C21H21N2O [M+H] 317.1604, found 317.1601.
2-苯乙基-N-(喹啉-8-基)丁-3-烯酰胺(1j): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.98 (s, 1H), 8.86~8.68 (m, 2H), 8.13 (dd, J=8.3, 1.7 Hz, 1H), 7.56~7.40 (m, 3H), 7.31~7.16 (m, 5H), 6.05 (ddd, J=17.1, 10.2, 8.6 Hz, 1H), 5.47~5.26 (m, 2H), 3.20 (q, J=7.6 Hz, 1H), 2.73 (dt, J=8.8, 6.2 Hz, 2H), 2.51~2.30 (m, 1H), 2.13~1.89 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 171.76, 148.26, 141.57, 138.58, 136.82, 136.33, 134.51, 128.61, 128.45, 127.40, 125.98, 121.61, 121.59, 118.54, 116.49, 52.60, 33.34, 33.29; HRMS (ESI-TOF) calcd for C21H21N2O [M+H] 317.1607, found 317.1605.
2-(4-氟苄基)-N-(喹啉-8-基)丁-3-烯酰胺(1k): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.90 (s, 1H), 8.85~8.68 (m, 2H), 8.11 (dd, J=8.3, 1.7 Hz, 1H), 7.54~7.45 (m, 2H), 7.40 (dd, J=8.3, 4.2 Hz, 1H), 7.23~7.17 (m, 2H), 6.96~6.87 (m, 2H), 6.03 (ddd, J=17.3, 10.0, 8.6 Hz, 1H), 5.38~5.21 (m, 2H), 3.48~3.30 (m, 2H), 3.00~2.89 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 171.03, 162.76, 160.33, 148.26, 148.23, 138.47, 136.33, 136.30, 136.13, 134.82, 134.79, 134.31, 130.71, 130.63, 127.91, 127.37, 127.33, 121.68, 121.64, 121.60, 118.85, 116.46, 115.24, 115.03, 55.25, 37.32; HRMS (ESI-TOF) calcd for C20H18FN2O [M+H] 321.3710, found 321.3709.
2-(环丁基甲基)-N-(喹啉-8-基)丁-3-烯酰胺(1l): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.94 (s, 1H), 8.84~8.72 (m, 2H), 8.15 (dd, J=8.3, 1.7 Hz, 1H), 7.63~7.34 (m, 3H), 6.01 (ddd, J=17.1, 10.1, 8.7 Hz, 1H), 5.38~5.18 (m, 2H), 3.20~2.99 (m, 1H), 2.50~2.34 (m, 1H), 2.16~1.99 (m, 3H), 1.89~1.64 (m, 5H); 13C NMR (101 MHz, CDCl3) δ: 170.34, 148.37, 138.40, 136.41, 133.87, 127.93, 127.38, 122.05, 121.74, 121.39, 116.89, 49.27, 37.41, 33.86, 28.44, 28.23, 28.14, 18.34, 15.48; HRMS (ESI-TOF) calcd for C18H21N2O [M+H] 281.1604, found 281.1606.

3.2.2 3-氰基-N-(喹啉-8-基)丁酰胺(3a)的合成

向10 mL反应管中加入1a (42.6 mg, 0.2 mmol)、碳酸铯(70.1 mg, 0.2 mmol)、TMSCN (0.4 mmol)、去离子水(0.12 mmol)和2 mL的DMF, 氮气保护, 在90 ℃下反应12 h. 反应结束后使用乙酸乙酯(30 mL)萃取两次, 合并有机相, 用无水硫酸钠干燥, 减压浓缩, 通过柱层析[V(石油醚)∶V(乙酸乙酯)=20∶1]纯化得到3-氰基- N-(喹啉-8-基)丁酰胺(3a), 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.81 (s, 1H), 8.73~8.63 (m, 2H), 8.09 (dd, J=8.3, 1.7 Hz, 1H), 7.48~7.37 (m, 3H), 3.32~3.23 (m, 1H), 2.92 (dd, J=15.5, 6.8 Hz, 1H), 2.70 (dd, J=15.5, 7.6 Hz, 1H), 1.38 (d, J=7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ: 166.89, 148.24, 138.07, 136.62, 133.80, 127.95, 127.36, 122.29, 122.13, 121.78, 116.90, 41.28, 21.89, 17.78; HRMS (ESI-TOF) calcd for C14H14N3O [M+H] 240.1104, found 240.1101.
3b~3l采用与3a相同的方法合成得到.
3-氰基-2-(环丙基甲基)-N-(喹啉-8-基)丁酰胺(3b): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.88 (s, 1H), 8.74~8.55 (m, 2H), 8.01 (dd, J=8.3, 1.7 Hz, 1H), 7.44~7.24 (m, 3H), 3.06~2.86 (m, 1H), 2.57 (td, J=10.2, 4.2 Hz, 1H), 1.70 (d, J=6.9 Hz, 2H), 1.23 (d, J=7.0 Hz, 3H), 0.71~0.53 (m, 1H), 0.36~0.18 (m, 2H), -0.00 (tdd, J=9.2, 8.2, 4.3 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ: 170.46, 148.32, 136.42, 133.95, 127.94, 127.40, 122.00, 121.71, 116.91, 51.48, 35.38, 27.85, 15.55, 9.04, 5.01, 4.39; HRMS (ESI-TOF) calcd for C18H20N3O [M+H] 294.1504, found 294.1506.
2-(1-氰乙基)-N-(喹啉-8-基)戊-4-烯酰胺(3c): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.96 (s, 1H), 8.90~8.73 (m, 2H), 8.17 (dd, J=8.3, 1.7 Hz, 1H), 7.62~7.40 (m, 3H), 5.94~5.74 (m, 1H), 5.36~5.02 (m, 2H), 3.12 (dd, J=7.2, 6.0 Hz, 1H), 2.81~2.66 (m, 2H), 2.66~2.55 (m, 1H), 1.46 (d, J=7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ: 169.52, 148.32, 138.39, 136.42, 133.82, 133.48, 127.93, 127.36, 122.10, 121.74, 121.12, 119.01, 116.94, 50.37, 34.47, 27.50, 15.45; HRMS (ESI-TOF) calcd for C17H18N3O [M+H] 280.1504, found 280.1506.
3-氰基-2-甲基-N-(喹啉-8-基)丁酰胺(3d): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 10.03 (s, 1H), 8.88~8.69 (m, 2H), 8.18 (dd, J=8.3, 1.7 Hz, 1H), 7.66~7.40 (m, 3H), 3.22~3.16 (m, 1H), 2.97~2.89 (m, 1H), 1.52 (d, J=7.1 Hz, 3H), 1.43 (d, J=7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ: 172.60, 148.19, 137.99, 136.41, 134.48, 127.96, 127.42, 121.56, 121.52, 117.29, 116.48, 47.00, 16.97; HRMS (ESI-TOF) calcd for C15H16N3O [M+H] 254.1201, found 254.1202.
3-氰基-2-乙基-N-(喹啉-8-基)丁酰胺(3e): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.98 (s, 1H), 8.93~8.73 (m, 2H), 8.17 (dd, J=8.3, 1.7 Hz, 1H), 7.62~7.37 (m, 3H), 3.14~3.04 (m, 1H), 2.63 (ddd, J=9.4, 6.8, 5.0 Hz, 1H), 2.03~1.93 (m, 1H), 1.86 (dtd, J=13.8, 7.3, 5.1 Hz, 1H), 1.45 (d, J=7.2 Hz, 3H), 1.08 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 170.29, 148.35, 138.39, 136.44, 133.85, 127.93, 127.35, 122.08, 121.73, 121.40, 116.93, 52.45, 27.80, 23.45, 15.44, 11.74; HRMS (ESI- TOF) calcd for C16H18N3O [M+H] 268.1404, found 268.1406.
2-(1-氰乙基)-N-(喹啉-8-基)庚-6-烯酰胺(3f): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.99 (s, 1H), 8.95~8.71 (m, 2H), 8.17 (dd, J=8.3, 1.7 Hz, 1H), 7.63~7.40 (m, 3H), 5.88~5.70 (m, 1H), 5.06~4.89 (m, 2H), 3.08 (p, J=7.1 Hz, 1H), 2.69 (ddd, J=9.9, 6.6, 4.7 Hz, 1H), 2.12 (t, J=7.1 Hz, 2H), 2.02~1.92 (m, 1H), 1.82~1.73 (m, 1H), 1.57 (ddd, J=7.4, 4.5, 2.0 Hz, 2H), 1.44 (d, J=7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ: 170.22, 148.36, 138.39, 137.80, 136.43, 133.82, 127.93, 127.34, 122.11, 121.76, 121.34, 116.91, 115.32, 50.83, 33.52, 29.62, 28.16, 26.46, 15.45; HRMS (ESI-TOF) calcd for C17H18N3O [M+H] 280.1404, found 280.1402.
3-氰基-2-环己基-N-(喹啉-8-基)丁酰胺(3g): 黄色油状液体. 1H NMR (400 MHz, Chloroform-d) δ: 9.91 (s, 1H), 8.96~8.77 (m, 2H), 8.18 (dd, J=8.3, 1.7 Hz, 1H), 7.56~7.39 (m, 3H), 3.17 (dd, J=7.2, 5.8 Hz, 1H), 2.34 (dd, J=9.1, 5.8 Hz, 1H), 2.02 (ddd, J=12.1, 9.0, 3.8 Hz, 2H), 1.81 (t, J=9.6 Hz, 2H), 1.69 (q, J=5.9 Hz, 2H), 1.46~1.03 (m, 10H); 13C NMR (101 MHz, Chloroform-d) δ: 169.99, 148.34, 136.42, 133.77, 127.94, 127.42, 122.00, 121.70, 116.93, 57.03, 38.36, 30.99, 30.69, 26.12, 26.06, 25.86, 25.40, 16.14; HEMS (ESI-TOF) calcd for C20H24N3O [M+H] 322.1804, found 422.1802.
2-(1-氰乙基)-N-(喹啉-8-基)壬酰胺(3h): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.98 (s, 1H), 8.84~8.80 (m, 2H), 8.17 (dd, J=8.3, 1.7 Hz, 1H), 7.55~7.53 (m, 2H), 7.47 (dd, J=8.3, 4.2 Hz, 1H), 3.12~3.04 (m, 1H), 2.68 (ddd, J=9.7, 6.6, 4.8 Hz, 1H), 1.94 (d, J=5.8 Hz, 1H), 1.79~1.70 (m, 1H), 1.45 (d, J=7.2 Hz, 4H), 1.39~1.31 (m, 2H), 1.31~1.20 (m, 7H), 0.85~0.81 (m, 3H); 13C NMR (101 MHz, CDCl3) δ: 170.40, 148.33, 138.39, 136.42, 133.86, 127.93, 127.35, 122.05, 121.74, 121.41, 116.89, 50.94, 31.73, 30.26, 29.48, 29.02, 28.14, 27.28, 22.57, 15.47, 14.04; HRMS (ESI-TOF) calcd for C21H28N3O [M+H] 338.2204, found 338.2200.
3-氰基-2-(4-甲基苄基)-N-(喹啉-8-基)丁酰胺(3i): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.76 (s, 1H), 8.90~8.65 (m, 2H), 8.15 (dd, J=8.3, 1.7 Hz, 1H), 7.55~7.36 (m, 3H), 7.20 (d, J=8.0 Hz, 2H), 7.06 (d, J=7.7 Hz, 2H), 3.24 (dd, J=13.8, 8.2 Hz, 1H), 3.11 (dd, J=13.8, 7.0 Hz, 1H), 3.00 (dd, J=7.2, 5.6 Hz, 1H), 2.89 (ddd, J=8.2, 7.0, 5.5 Hz, 1H), 2.24 (s, 3H), 1.47 (d, J=7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ: 169.47, 148.14, 136.57, 136.32, 134.43, 133.80, 129.52, 128.84, 127.84, 127.33, 122.01, 121.63, 116.91, 52.83, 36.30, 27.54, 20.99, 15.78; HRMS (ESI-TOF) calcd for C22H22N3O [M+H] 344.1701, found 344.1703.
3-氰基-2-苯乙基-N-(喹啉-8-基)丁酰胺(3j): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.99 (s, 1H), 8.90~8.74 (m, 2H), 8.19 (dd, J=8.3, 1.7 Hz, 1H), 7.60~7.45 (m, 3H), 7.31~7.20 (m, 5H), 3.06 (p, J=7.1 Hz, 1H), 2.88~2.82 (m, 1H), 2.74~2.63 (m, 2H), 2.34 (dddd, J=13.8, 10.3, 8.8, 5.2 Hz, 1H), 2.06 (dddd, J=13.5, 9.2, 7.6, 4.2 Hz, 1H), 1.42 (d, J=7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ: 169.99, 148.36, 140.51, 138.42, 136.44, 133.80, 128.64, 128.51, 127.96, 127.36, 126.34, 122.21, 121.80, 121.18, 117.00, 49.96, 33.24, 31.82, 28.36, 15.43; HRMS (ESI-TOF) calcd for C22H22N3O [M+H] 294.1504, found 294.1506.
3-氰基-2-(4-氟苄基)-N-(喹啉-8-基)丁酰胺(3k): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.72 (s, 1H), 8.80~8.72 (m, 2H), 8.17~8.13 (m, 1H), 7.54~7.51 (m, 2H), 7.44 (dd, J=8.4, 4.4 Hz, 1H), 7.29~7.25 (m, 2H), 6.97~6.89 (m, 2H), 3.24 (dd, J=13.8, 9.0 Hz, 1H), 3.10 (dd, J=13.8, 6.3 Hz, 1H), 3.03 (dd, J=7.1, 5.6 Hz, 1H), 2.93~2.87 (m, 1H), 1.50~1.48 (m, 3H); 13C NMR (101 MHz, CDCl3) δ: 169.17, 148.30, 148.16, 136.52, 136.46, 133.57, 133.31, 133.27, 130.56, 130.48, 127.86, 127.35, 127.31, 122.18, 122.11, 121.79, 121.71, 120.91, 116.99, 116.81, 115.79, 115.58, 52.82, 41.32, 35.83, 27.76, 21.89, 17.80, 15.66; HRMS (ESI-TOF) calcd for C21H19N3O [M+H] 348.3911, found 349.3907.
3-氰基-2-(环丁基甲基)-N-(喹啉-8-基)-丁酰胺(3l): 黄色油状液体. 1H NMR (400 MHz, CDCl3) δ: 9.93 (s, 1H), 8.92~8.71 (m, 2H), 8.18 (dd, J=8.3, 1.7 Hz, 1H), 7.66~7.48 (m, 3H), 3.12~2.95 (m, 1H), 2.60 (ddd, J=10.1, 6.6, 4.6 Hz, 1H), 2.43 (qd, J=8.2, 6.5 Hz, 1H), 2.24~2.14 (m, 1H), 2.13~1.99 (m, 2H), 1.86~1.66 (m, 5H), 1.44 (d, J=7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ: 172.17, 148.24, 138.56, 137.11, 136.32, 134.53, 127.95, 127.42, 121.56, 121.46, 117.68, 116.41, 51.72, 39.21, 33.94, 28.52, 28.25, 18.48; HRMS (ESI-TOF) calcd for C19H22N3O [M+H] 308.1504, found 308.1506.
3-氰基-2,2,3,4-四氘代-N-(8-氨基喹啉)丁酰胺(4): 1H NMR (400 MHz, CDCl3) δ: 9.87 (s, 1H), 8.90~8.66 (m, 2H), 8.14 (dd, J=8.3, 1.7 Hz, 1H), 7.54~7.41 (m, 3H), 1.45~1.41 (m, 2H).
辅助材料(Supporting Information) 化合物1a~1l3a~3l的核磁共振氢谱、碳谱. 这些材料可以免费从本刊网站(http://sioc-journal.cn/)上下载.
(Cheng, F.)
[1]
Yang L.; Ji W.-W.; Lin E.; Li J.-L.; Fan W.-X.; Li Q.; Wang H. Org. Lett. 2018, 20, 1924.

[2]
Wang W.; Ding C.; Li Y.; Li Z.; Li Y.; Peng L.; Yin G. Angew. Chem., Int. Ed. 2019, 58, 4612.

[3]
Han C.; Fu Z.; Guo S.; Fang X.; Lin A.; Yao H. ACS Catal. 2019, 9, 4196.

[4]
Longwitz L.; Werner T. Angew. Chem., Int. Ed. 2020, 59, 2760.

[5]
Song P.; Zhu S. ACS Catal. 2020, 10, 13165.

[6]
Tian T.; Wang X.; Lv L.; Li Z. Chem. Commun. 2020, 56, 14637.

[7]
Hirao Y.; Katayama Y.; Mitsunuma H.; Kanai M. Org. Lett. 2020, 22, 8584.

DOI PMID

[8]
Liu T.; Yang Y.; Wang Y. Angew. Chem., Int. Ed. 2020, 59, 14256.

[9]
Czyz M. L.; Taylor M. S.; Horngren T. H.; Polyzos A. ACS Catal. 2021, 11, 5472.

[10]
Zhan Y.; Zhao Y.; Du Q.; Rui J.; Chen R.; Zheng X.; Wu X. Green Chem. 2021, 23, 3250.

[11]
Zhang L.-W.; Deng X.-J.; Zhang D.-X.; Tian Q.-Q.; He W. J. Org. Chem. 2021, 86, 5152.

[12]
Simlandy A. K.; Rodphon W.; Alturaifi T. M.; Mai B. K.; Ni H.-Q.; Gurak J. A.; Liu P.; Engle K. M. ACS Catal. 2022, 12, 13755.

[13]
Wu X.; Gannett C. N.; Liu J.; Zeng R.; Novaes L. F. T.; Wang H.; Abruña H. D.; Lin S. J. Am. Chem. Soc. 2022, 144, 17783.

[14]
Yue W. J.; Day C. S.; Rucinski A. B.; Martin R. Org. Lett. 2022, 24, 5109.

[15]
Zhao F.; Xu J.-X.; Wu F.-P.; Wu X.-F. J. Catal. 2023, 417, 379.

[16]
Zhang P. -Z.; Zhang L.; Zou J. -P.; Zhang W. Org. Lett. 2017, 19, 5537.

[17]
Song L.; Fu N.; Ernst B. G.; Lee W.-H.; Frederick M. O.; Lin S. Nat. Chem. 2020, 12, 747.

DOI PMID

[18]
Israr M.; Xiong H.; Li Y.; Bao H. -L. Adv. Synth. Catal. 2020, 362, 2211.

[19]
Li X.-Y.; Tao P.-F.; Huang G.-B. Chin. J. Org. Chem. 2022, 42, 4169 (in Chinese).

( 李秀英, 陶萍芳, 黄国保, 有机化学, 2022, 42, 4169.)

DOI

[20]
Liu J.-C.; Wan J.-P.; Liu Y.-Y. Org. Chem. Front. 2024, 11, 597.

[21]
Xu Z.; Fu L.; Fang X.; Huang B.; Zhou L.; Wan J.-P. Org. Lett. 2021, 23, 5049.

[22]
Zhang X.-Y.; Geng H.-H.; Zhang S.-L. Chin. J. Org. Chem. 2023, 43, 1510 (in Chinese).

( 张心予., 耿慧慧, 张士磊, 有机化学, 2023, 43, 1510.)

DOI

文章导航

/